Area of research
Otorhinolaryngology · Periodontics
Research interest
Research interests include Head and Neck Cancer Studies, Oral Health Pathology and Treatment, Cancer Genomics and Diagnostics, and Cancer-related Molecular Pathways.
Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer.
Supersensitive and robust disease monitoring in oropharyngeal cancer patients by circulating tumor HPV-DNA sequencing (ctHPV-DNAseq).
The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets
Supplementary Figure S4 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Supplementary Figure S9 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Author Correction: Hallmarks of a genomically distinct subclass of head and neck cancer.
Supplementary Figure S7 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Supplementary Figure S10 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Profiling of psychoneurological symptoms in newly diagnosed head and neck cancer patients.
Supplementary Tables S1-2 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Supplementary Figure S3 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Supplementary Figure S8 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Supplementary Figure S5 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Supplementary Figure S6 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Supplementary Figure S12 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Supplementary Figure S11 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
New insights into the genetic progression of cancer through longitudinal analysis of oral lesions.
Supplementary Figure S2 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Supplementary Figure S1 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Hallmarks of a genomically distinct subclass of head and neck cancer.
An Antibody-Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy.
Secretome and immune cell attraction analysis of head and neck cancers.
Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer.
The value of regular follow-up of oral leukoplakia for early detection of malignant transformation.
Pharmacodynamics and biodistribution of [195mPt]cisplatin(CISSPECT®) in head and neck squamous cell carcinoma
Gemcitabine as chemotherapy of head and neck cancer in Fanconi anemia patients
Supplementary Figure S3 from An Antibody–Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy
Supplementary Table 2 from An Antibody–Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy
Data from An Antibody–Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy
Data from An Antibody–Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy